Docuscreen
About
What does Docuscreen do?
Docuscreen offers an AI-driven solution designed to automate the review and analysis of legal and business documents. It helps users quickly extract key information, identify risks, and ensure compliance, streamlining complex document workflows for legal professionals and businesses.
What industry does Docuscreen operate in?
Docuscreen operates in LegalTech, Document Analysis, Contract Management, Compliance, Workflow Automation, Generative AI.
Does Docuscreen have an affiliate program?
Yes, Docuscreen has an affiliate program. The program runs on Self-hosted affiliate. Register here: https://docuscreen.io/affiliates
Unbeta scans AI-built apps for broken flows, security holes, and legal exposure, providing copy-paste fix prompts.
Pshat is an AI-powered application that helps users understand Hebrew documents by providing plain-language explanations in English or Russian.
Shisai checks whether AI-drafted text is backed by the records it cites, and produces evidence a compliance officer can file. Deterministic. No model in the judgement.
CounselVeil analyzes legal matters within your own cloud account, ensuring no data leaves your control and no model trains on your sensitive information.
Delayanalysis AI helps construction project teams analyze the causes and impacts of schedule delays, identify delay events, calculate delay impacts, allocate responsibility, and support schedule claim documentation.
A content hub and informational resource exploring the integration and future of AI in virtual data rooms for M&A and other transactions.
Brilliuslaw is a stealth-mode startup founded in 2026, operating in the LegalTech and Agentic AI sectors.
Gestión de causas y tramitación para estudios jurídicos.
An entrant is a company tagged LegalTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 12 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.